Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology
| Autor: | Harsimran Singh, Jordan E. Pinsker, Alexandra Constantin, Molly McElwee Malloy, Lars Müller, Michelle L. Manning, Steph Habif, Scott Leas |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Insulin pump
Adult Blood Glucose Male medicine.medical_specialty Technology Adolescent Endocrinology Diabetes and Metabolism Control (management) 030209 endocrinology & metabolism Artificial pancreas 03 medical and health sciences Young Adult 0302 clinical medicine Endocrinology Insulin Infusion Systems Glycemic control Quality of life Diabetes mellitus medicine Humans Hypoglycemic Agents Insulin 030212 general & internal medicine Patient Reported Outcome Measures Glycemic Type 1 diabetes Patient-reported outcomes business.industry Blood Glucose Self-Monitoring Original Articles Middle Aged medicine.disease United States Medical Laboratory Technology Diabetes Mellitus Type 1 Automated insulin delivery Physical therapy Quality of Life Female business Psychosocial |
| Zdroj: | Diabetes Technology & Therapeutics |
| ISSN: | 1557-8593 |
| Popis: | Background: The t:slim X2™ insulin pump with Control-IQ™ technology, an advanced hybrid closed-loop system, became available in the United States in early 2020. Real-world outcomes with use of this system have not yet been comprehensively reported. Methods: Individuals with type 1 diabetes (T1D) (≥14 years of age) who had ≥21 days of pump usage data were invited via email to participate. Participants completed psychosocial questionnaires (Technology Acceptance Scale [TAS], well-being index [WHO-5], and Diabetes Impact and Devices Satisfaction [DIDS] scale) at timepoint 1 (T1) (at least 3 weeks after starting Control-IQ technology) and the DIDS and WHO-5 at timepoint 2 (T2) (4 weeks from T1). Patient-reported outcomes (PROs) and glycemic outcomes were reviewed at each timepoint. Results: Overall, 9,085 potentially eligible individuals received the study invite. Of these, 3,116 consented and subsequently 1,435 participants completed questionnaires at both T1 and T2 and had corresponding glycemic data available on the t:connect® web application. Time in range was 78.2% (70.2%-85.1%) at T1 and 79.2% (70.3%-86.2%) at T2. PROs reflected high device-related satisfaction and reduced diabetes impact at T2. Factors contributing to high trust in the system included sensor accuracy, improved diabetes control, reduction in extreme blood glucose levels, and improved sleep quality. In addition, participants reported improved quality of life, ease of use, and efficient connectivity to the continuous glucose monitoring system as being valuable features of the system. Conclusions: Continued real-world use of the t:slim X2 pump with Control-IQ technology showed improvements in psychosocial outcomes and persistent achievement of recommended TIR glycemic outcomes in people with T1D. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|